CannonCPBlazingMAGiuglianoRP. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med2015; 372: 2387–2397.
2.
RobinsonJGFarnierMKrempfM. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med2015; 372: 1489–1499.
3.
SabatineMSGiuglianoRPWiviottSD. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med2015; 372: 1500–1509.
4.
BaigentCKeechAKearneyPM. Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet2005; 366: 1267–1278.
5.
VoightBFPelosoGMOrho-MelanderM. Plasma HDL cholesterol and risk of myocardial infarction: A mendelian randomisation study. Lancet2012; 380: 572–580.
6.
Myocardial Infarction Genetics Consortium Investigators. Inactivating mutations in NPC1L1 and protection from coronary heart disease. N Engl J Med2014; 371: 2072–2082.
7.
SwerdlowDIPreissDKuchenbaeckerKB. HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: Evidence from genetic analysis and randomised trials. Lancet2015; 385: 351–361.
